Market Overview

Thermo Fisher Scientific to Sell its Cell Culture, Gene Modulation and Magnetic Beads Businesses to GE Healthcare for $1.06B

Related TMO
UPDATE: 3D, Thermo Fisher Scientific Partner On National Education Reach
UBS Thinks TMO + PLL Could Create Bio-Production Powerhouse
Can Pacific Biosciences Grow In A Market Dominated By Low Cost Sequencers? (Seeking Alpha)

Thermo Fisher Scientific (NYSE: TMO) today announced that it has signed an agreement to sell its
cell culture (sera and media), gene modulation and magnetic beads
businesses to GE Healthcare, a unit of General Electric Company (NYSE: GE), for approximately $1.06 billion. The businesses will become part of
GE Healthcare's Life Sciences division.

See full press release

Posted-In: News Guidance Asset Sales Management M&A Global


Related Articles (LIFE + GE)

Around the Web, We're Loving...